Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 9/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437878 | 0.95 | UTS2R (0.47) | UTS2RACHEBCHECCR3POLB | |
| SCHEMBL12437863 | 0.94 | UTS2R (0.46) | UTS2RACHEBCHECCR3POLB | |
| SCHEMBL12437905 | 0.90 | UTS2R (0.44) | UTS2RACHEBCHECCR3SLC2A1 | |
| SCHEMBL12437856 | 0.87 | UTS2R (0.46) | UTS2R | |
| SCHEMBL12437792 | 0.86 | UTS2R (0.50) | UTS2RACHEBCHECCR3POLB | |
| SCHEMBL12437802 | 0.85 | UTS2R (0.47) | UTS2RACHEBCHECCR3POLB | |
| SCHEMBL12437794 | 0.84 | CCR3 (0.52) | UTS2RACHEBCHECCR3POLB | |
| SCHEMBL12437918 | 0.84 | UTS2R (0.44) | UTS2RACHEBCHECCR3POLB | |
| SCHEMBL12437795 | 0.84 | UTS2R (0.47) | UTS2RACHEBCHECCR3POLB | |
| SCHEMBL12437793 | 0.84 | CCR3 (0.51) | UTS2RACHEBCHECCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | UTS2R 854/4885ACHE 3354/4885BCHE 3384/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | UTS2R 854/4885ACHE 3354/4885BCHE 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.